Scancell signs manufacturing agreement for its Moditope anti-cancer platform The AIM-listed firm said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system [View article] Tuesday 3 April 2018 10:40 Categories: Media Coverage Modi-1 Moditope Year - 2018 Previous Post << >> Next Post